Name | LLY-283 |
---|
Description | LLY-283 is a potent, selective and oral protein arginine methyltransferase 5 (PRMT5) inhibitor, with an IC50 of 22 nM and a Kd of 6 nM for PRMT5:MEP50 complex, and shows antitumor activity. |
---|---|
Related Catalog | |
Target |
IC50: 22 nM (PRMT5:MEP50)[1] Ki: 6 nM (PRMT5:MEP50)[1] |
In Vitro | LLY-283 is a potent, oral and selective arginine methyltransferase 5 (PRMT5) inhibitor, with an IC50 of 22 nM in vitro and 25 nM in cells, as well as a Kd of 6 nM for PRMT5:MEP50 complex in vitro; LLY-283 inhibits the proliferation of A375 cell with an IC50 of 46 nM[1]. |
In Vivo | LLY-283 (20 mg/kg; p.o., QD (once a day)) causes a significant inhibition on tumor growth in mice bearing A375 cells after treatment for 28 days[1]. |
References |
Molecular Formula | C17H18N4O4 |
---|---|
Molecular Weight | 342.35 |
Storage condition | -20℃ |